InsidersTradesSigma
Follow the Cumberland Pharmaceuticals INC share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Cumberland Pharmaceuticals INC has logged 224 reports. Market capitalisation: €114.8m. The latest transaction was disclosed on 20 March 2026 (Attribution). Among the most active insiders: Krogulski Kenneth. The full history is accessible without an account.
224
Insider Decl.
n/a
Thresholds
€22,083
109 ops.
Buy Volume
n/a
n/a
Sell Volume
60Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,688 of 29,055 companies
34.8
score / 100
Value30
Quality39
FCF yld4.1%
Earn yld-2.4%
EV/EBITDA42.8x
ROE-14%
Gross mgn85%
Net mgn-6.4%
Debt/EBITDA3.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 March 2026
Declarations224 total
1,800 shares@ US$2.8017.8% of flowCommon StockSEC:0001632384-26-000002:0
1,800 shares@ US$2.8026.5% of flowCommon StockSEC:0001087294-26-000040:0
1,800 shares@ US$2.8018.3% of flowCommon StockSEC:0001087294-26-000039:0
1,800 shares@ US$2.808.4% of flowCommon StockSEC:0001087294-26-000037:0
1,800 shares@ US$2.8018.9% of flowCommon StockSEC:0001087294-26-000036:0
5,845 shares@ US$3.065.3% of flowCommon StockSEC:0001628280-26-019514:0
18 shares@ US$2.360.0% of flowCommon StockSEC:0001087294-26-000004:0
18 shares@ US$2.360.2% of flowCommon StockSEC:0001087294-26-000006:0
124 shares@ US$2.360.5% of flowCommon StockSEC:0001087294-26-000002:0
4 shares@ US$2.360.0% of flowCommon StockSEC:0001087294-26-000008:0
13 shares@ US$2.800.1% of flowCommon StockSEC:0001490829-25-000007:0
6 shares@ US$2.800.1% of flowCommon StockSEC:0001087294-25-000029:0
13 shares@ US$2.800.0% of flowCommon StockSEC:0001087294-25-000027:0
68 shares@ US$2.800.3% of flowCommon StockSEC:0001087294-25-000025:0
68 shares@ US$3.310.4% of flowCommon StockSEC:0001695580-25-000004:0
6 shares@ US$3.310.1% of flowCommon StockSEC:0001684087-25-000008:0
13 shares@ US$3.310.2% of flowCommon StockSEC:0001490829-25-000005:0
13 shares@ US$3.310.0% of flowCommon StockSEC:0001075050-25-000006:0
4 shares@ US$3.540.1% of flowCommon StockSEC:0001684087-25-000004:0
12 shares@ US$3.540.2% of flowCommon StockSEC:0001087294-25-000008:0
12 shares@ US$3.540.0% of flowCommon StockSEC:0001087294-25-000007:0
62 shares@ US$3.540.4% of flowCommon StockSEC:0001087294-25-000006:0
6 shares@ US$3.440.1% of flowCommon StockSEC:0001628280-25-041989:0
Canonical exit: 30 Oct 2025 (T+90)
13 shares@ US$3.440.2% of flowCommon StockSEC:0001628280-25-041987:0
Canonical exit: 30 Oct 2025 (T+90)
13 shares@ US$3.440.0% of flowCommon StockSEC:0001628280-25-041985:0
Canonical exit: 30 Oct 2025 (T+90)
25 of 224 declarations
关于 Cumberland Pharmaceuticals INC
Cumberland Pharmaceuticals Inc. 是一家专业制药公司，在美国纳斯达克上市，股票代码为 CPIX。公司总部位于田纳西州纳什维尔，开发、收购和商业化品牌处方药，其战略重点是未满足医疗需求仍然显著的治疗利基市场。对于法国、比利时或瑞士的法语投资者而言，Cumberland 符合美国中小型医疗保健公司的形象，其特点是商业执行和有针对性的开发相结合，而非广泛的平台生物技术公司。该公司成立于 2000 年代初，通过收购成熟品牌的权利、重振这些资产的增长以及通过其开发附属公司维持更具选择性的早期开发管线来建立业务。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm?utm_source=openai)） Cumberland 的核心业务围绕 FDA 批准的品牌产品，主要用于医院环境、专科护理和选定的利基适应症。该公司还通过 Cumberland Emerging Technologies 维护开发资产，以帮助推进早期候选药物。最近的文件和新闻稿中提及的产品和资产包括 Vibativ、Sancuso 和 ifetroban 项目。在竞争方面，Cumberland 定位为一家敏捷的专业制药运营商，旨在将现有资产货币化，同时在具有显著未满足医疗需求的适应症中创造价值。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001087294/000108729426000020/cpix-20251231.htm?utm_source=openai)） 从地理上看，该集团仍然是一家总部设在美国的美国公司，但随着其某些产品在海外市场的扩张和获得批准，其国际足迹日益扩大。最近的披露强调了新的国际批准和持续的产品组合进展。2025 年，Cumberland 报告了收入增长和更强的运营执行力；2026 年，它宣布与 Apotex 的一家附属公司进行一项重大战略交易，以 100 million 美元整合其商业业务，同时将重点放在孤儿药候选药物和更高回报的开发项目上。这是一个重要的战略转折点，因为它减少了公司对成熟商业品牌的依赖，并增加了可用于下一阶段增长的资本。（[investor.cumberlandpharma.com](https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-31-fourth-quarter-2025?utm_source=openai)） 总而言之，Cumberland Pharmaceuticals Inc. 是一家在纳斯达克上市的美国专业制药公司，结合了已上市产品、品牌资产管理和重点管线开发。对于国际股权投资者而言，其主要吸引力在于其专业制药模式、严谨的产品组合方法以及最近的监管和战略催化剂。最新的公司通讯指出，2025 年运营势头有所改善，随后在 2026 年初围绕公司最有前途的资产进行了重大重新定位。（[investor.cumberlandpharma.com](https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-31-fourth-quarter-2025?utm_source=openai)）
